Survival traits for breast, lung, prostate, colorectal cancers are passed from parents to children

November 02, 2007

Children whose parents had good survival after diagnosis of breast, lung, prostate, or colorectal cancers have better survival rates for cancers at the same site than children whose parents had died from these conditions. These are the conclusions of authors of an Article published in the November issue of The Lancet Oncology.

Dr Linda Lindstrom, Karolinska Institute, Stockholm, Sweden, and colleagues used a population-based Swedish family database, that included three million families and more than a million individuals with cancer. They analysed child survival in relation to parental survival using statistical techniques and computer modelling.

They found that children with the same cancer as their parent and whose parent had died within 10 years of diagnosis showed significantly worse survival for breast, lung, colorectal, and prostate cancers, compared with children whose parents had good survival. The increased risk to the children whose parents had died earlier was 75% for breast cancer, 107% for prostate cancer, 44% for colorectal cancer, and 39% for lung cancer. Risk of death for these children also increased by degree of worsening survival outcome for their parents.

The authors say: "In conclusion, our findings provide support for the hypothesis that cancer-specific survival of a patient can be predicted from previous parental survival from cancer at the same site. Consequently, molecular studies that highlight the genetic determinants of inherited survival in cancers are needed. In a clinical setting, information on poor survival in a family might be vital in accurately predicting tumour progression in the newly diagnosed individual."

In an accompanying Comment, Dr Ora Paltiel, Hadassah-Hebrew University Medical Centre, Jerusalem, Israel, says: "Lindstrom and colleagues findings, if confirmed, might have practical implications for family members and their physicians. For example, additional useful information might now be available for children who have a parent affected by a rapidly fatal cancer, which could act as a basis for specific therapeutic and preventative decisions â€"for example active treatment versus observation in prostate cancer. Research on patterns of disease in families has led to valuable clues about cancer genetics and susceptibility syndromes."
-end-
Papers associated with the press release are listed below:
http://www.eurekalert.org/jrnls/lance/Familycancersurvival.pdf
http://www.eurekalert.org/jrnls/lance/TLOcancersurvivalcomment.pdfDr Linda Lindstrom, Karolinska Institute, Stockholm, Sweden T) +46-8-524 823 56 E) linda.lindstrom@ki.se

Dr Ora Paltiel, Hadassah-Hebrew University Medical Centre, Jerusalem, Israel T) +1-646-309-4003 / +1-212-639-2785 E) ora@vms.huji.ac.il Dr Linda Lindstrom, Karolinska Institute, Stockholm, Sweden T) +46-8-524 823 56 E) linda.lindstrom@ki.se

Dr Ora Paltiel, Hadassah-Hebrew University Medical Centre, Jerusalem, Israel T) +1-646-309-4003 / +1-212-639-2785 E) ora@vms.huji.ac.il

Lancet

Related Prostate Cancer Articles from Brightsurf:

Low risk of cancer spread on active surveillance for early prostate cancer
Men undergoing active surveillance for prostate cancer have very low rates - one percent or less - of cancer spread (metastases) or death from prostate cancer, according to a recent study published in the Journal of Urology®, an Official Journal of the American Urological Association (AUA).

ESMO 2020: Breast cancer drug set to transform prostate cancer treatment
A drug used to treat breast and ovarian cancer can extend the lives of some men with prostate cancer and should become a new standard treatment for the disease, concludes a major trial which is set to change clinical practice.

Major trial shows breast cancer drug can hit prostate cancer Achilles heel
A drug already licensed for the treatment of breast and ovarian cancers is more effective than targeted hormone therapy at keeping cancer in check in some men with advanced prostate cancer, a major clinical trial reports.

The Lancet: Prostate cancer study finds molecular imaging could transform management of patients with aggressive cancer
Results from a randomised controlled trial involving 300 prostate cancer patients find that a molecular imaging technique is more accurate than conventional medical imaging and recommends the scans be introduced into routine clinical practice.

Common genetic defect in prostate cancer inspires path to new anti-cancer drugs
Researchers found that, in prostate cancer, a mutation leading to the loss of one allele of a tumor suppressor gene known as PPP2R2A is enough to worsen a tumor caused by other mutations.

First prostate cancer therapy to target genes delays cancer progression
For the first time, prostate cancer has been treated based on the genetic makeup of the cancer, resulting in delayed disease progression, delayed time to pain progression, and potentially extending lives in patients with advanced, metastatic prostate cancer, reports a large phase 3 trial.

Men taking medications for enlarged prostate face delays in prostate cancer diagnosis
University of California San Diego School of Medicine researchers report that men treated with medications for benign prostatic hyperplasia (enlarged prostate) experienced a two-year delay in diagnosis of their prostate cancer and were twice as likely to have advanced disease upon diagnosis.

CNIO researchers confirm links between aggressive prostate cancer and hereditary breast cancer
The study has potential implications for families with members suffering from these types of tumours who are at an increased risk of developing cancer.

Distinguishing fatal prostate cancer from 'manageable' cancer now possible
Scientists at the University of York have found a way of distinguishing between fatal prostate cancer and manageable cancer, which could reduce unnecessary surgeries and radiotherapy.

Researchers find prostate cancer drug byproduct can fuel cancer cells
A genetic anomaly in certain men with prostate cancer may impact their response to common drugs used to treat the disease, according to new research at Cleveland Clinic.

Read More: Prostate Cancer News and Prostate Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.